MediWound Ltd. (MDWD) Downgraded to “Sell” at Zacks Investment Research
According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “
A number of other equities research analysts also recently weighed in on MDWD. Jefferies Group lowered their price objective on shares of MediWound from $15.00 to $13.00 and set a buy rating for the company in a research report on Friday, July 29th. Wells Fargo & Co. assumed coverage on shares of MediWound in a research report on Wednesday, August 17th. They set an outperform rating and a $14.00 price objective for the company. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $13.63.
Shares of MediWound (NASDAQ:MDWD) traded down 1.2296% during midday trading on Wednesday, reaching $5.6793. 9,395 shares of the company were exchanged. MediWound has a 52-week low of $5.10 and a 52-week high of $10.47. The stock’s market capitalization is $124.21 billion. The company’s 50-day moving average price is $6.60 and its 200 day moving average price is $7.43.
MediWound (NASDAQ:MDWD) last released its earnings results on Monday, November 14th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.26). The company earned $0.52 million during the quarter, compared to the consensus estimate of $0.61 million. MediWound had a negative net margin of 1,776.06% and a negative return on equity of 128.17%. The company’s revenue was up 420.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.17) EPS. On average, equities analysts predict that MediWound will post ($1.01) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of MDWD. Migdal Insurance & Financial Holdings Ltd. purchased a new position in MediWound during the second quarter worth about $13,302,000. Wellington Management Group LLP raised its position in MediWound by 10.7% in the first quarter. Wellington Management Group LLP now owns 1,044,703 shares of the biopharmaceutical company’s stock worth $8,431,000 after buying an additional 100,723 shares during the last quarter. Baker BROS. Advisors LP purchased a new position in MediWound during the third quarter worth about $1,740,000. United Services Automobile Association raised its position in MediWound by 1.3% in the third quarter. United Services Automobile Association now owns 125,080 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 1,640 shares during the last quarter. Finally, Citadel Advisors LLC raised its position in MediWound by 4.5% in the third quarter. Citadel Advisors LLC now owns 33,622 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 1,456 shares during the last quarter. 26.67% of the stock is owned by hedge funds and other institutional investors.
MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.
Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.